Form 4: Black Diamond Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Prakash Raman acquires 30,550 stock options in Black Diamond Therapeutics.
Summary
- On June 6, 2024, Prakash Raman, a director of Black Diamond Therapeutics, Inc. [BDTX], acquired 30,550 stock options.
- The options have an exercise price of $4.65.
- The options vest fully on the earlier of June 6, 2025, or the Issuer's next annual meeting of stockholders, contingent upon continued service.
- The expiration date for the options is June 5, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing. The sentiment is neutral as it simply reports a transaction.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Prakash Raman acquired stock options. |
| 06/06/2025 | Earliest vesting date for the stock options. |
| 06/05/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.